Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ATHA 
Athira Pharma Inc (ATHA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/11/2025: ATHA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -1.91% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.91M USD | Price to earnings Ratio - | 1Y Target Price 0.55 |
Price to earnings Ratio - | 1Y Target Price 0.55 | ||
Volume (30-day avg) 198151 | Beta 3.01 | 52 Weeks Range 0.25 - 3.67 | Updated Date 04/1/2025 |
52 Weeks Range 0.25 - 3.67 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.52 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -55.23% | Return on Equity (TTM) -110.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -38934808 | Price to Sales(TTM) - |
Enterprise Value -38934808 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.31 | Shares Outstanding 39042400 | Shares Floating 27560062 |
Shares Outstanding 39042400 | Shares Floating 27560062 | ||
Percent Insiders 2.9 | Percent Institutions 51.81 |
Analyst Ratings
Rating 3 | Target Price 0.55 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Athira Pharma Inc
Company Overview
History and Background
Athira Pharma, Inc. was founded in 2011 and is focused on developing novel therapeutics for neurodegenerative diseases. They are dedicated to restoring neuronal health and slowing neurodegeneration. Early milestones involved preclinical research and securing funding for clinical trials.
Core Business Areas
- Neurological Therapeutics Development: Athira's primary focus is on the research and development of small molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
Leadership and Structure
The leadership team consists of experienced professionals in drug development and neuroscience. The organizational structure includes research, clinical development, and commercial operations departments.
Top Products and Market Share
Key Offerings
- Fosgonimeton: Fosgonimeton (ATH-1017) is Athira's lead investigational compound, a small molecule positive modulator of HGF/MET, designed to enhance the regenerative capacity of the brain. It is being developed for Alzheimer's disease and potentially other neurodegenerative conditions. There is currently no market share data, as it is still in clinical trials. Competitors in this space include companies developing other Alzheimer's treatments, such as Biogen (BIIB) and Eli Lilly (LLY).
Market Dynamics
Industry Overview
The pharmaceutical industry focused on neurodegenerative diseases is characterized by high unmet needs, significant research and development efforts, and regulatory hurdles. It is a competitive market with many players seeking innovative therapies.
Positioning
Athira Pharma is positioning itself as a leader in developing regenerative therapeutics for neurodegenerative diseases. Its competitive advantage lies in its novel approach to targeting the HGF/MET pathway to enhance neuronal health.
Total Addressable Market (TAM)
The global Alzheimer's disease market is estimated to reach hundreds of billions USD. Athira is positioned to capture a portion of this TAM if fosgonimeton proves successful and receives regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (HGF/MET modulation)
- Experienced leadership team
- Strong intellectual property position
Weaknesses
- Dependence on a single lead compound (fosgonimeton)
- Clinical trial risks
- Limited commercial infrastructure
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into other neurodegenerative diseases
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established pharmaceutical companies
- Funding availability
Competitors and Market Share
Key Competitors
- Biogen (BIIB)
- Eli Lilly (LLY)
- Roche (ROG.SW)
Competitive Landscape
Athira faces significant competition from larger, more established pharmaceutical companies. Its advantage lies in its novel therapeutic approach, but it must successfully navigate clinical trials and regulatory hurdles to compete effectively.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the expansion of its research and development programs and advancement of clinical trials.
Future Projections: Future growth is contingent on the successful completion of clinical trials and regulatory approval of its lead compound, fosgonimeton. Analyst estimates vary, but positive trial outcomes could significantly increase the company's value.
Recent Initiatives: Recent initiatives include the advancement of fosgonimeton into Phase 2/3 clinical trials for Alzheimer's disease.
Summary
Athira Pharma is a clinical-stage biopharmaceutical company focused on neurodegenerative diseases. Its strength lies in its unique approach with fosgonimeton, but clinical trial success is crucial. The company is currently burning cash and relies heavily on future success and additional funding. Competition from industry giants and potential regulatory setbacks pose significant risks.
Similar Companies
- BIIB
- LLY
- SAVA
- ACAD
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data are estimates and may vary. The AI-based rating is based on available information and should not be the sole basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Athira Pharma Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 2020-09-18 | President, CEO & Director Dr. Mark J. Litton M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 26 | Website https://www.athira.com |
Full time employees 26 | Website https://www.athira.com | ||
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.